Seeking Fresh Start From Its Troubles, Cassava Changes Its Name To Filana - KFF Health News
Cassava Sciences has rebranded as Filana Therapeutics following investigations and a failed Alzheimer's drug trial.Summary
Cassava Sciences is rebranding as Filana Therapeutics in an attempt to distance itself from past controversies, including a Department of Justice investigation, class-action lawsuits alleging scientific misconduct, and the failure of its Alzheimer’s drug, simufilam. The company has recently settled both the DOJ case and the class-action lawsuit.
In other pharmaceutical news, Novo Nordisk received a warning from the FDA for failing to report suspected side effects of its drugs, including weight loss medications like Wegovy. An analysis suggests Wegovy may carry a higher risk of a specific eye stroke compared to Ozempic. Hims & Hers Health Inc. has hired a former Lilly PR chief to bolster its weight-loss drug strategy.
Additionally, Medtronic is acquiring Scientia Vascular for $550 million, CSL is expanding its plasma-based medicines plant in Illinois with a $1.5 billion investment, and a trial has begun against Abbott regarding a formula for premature babies. AbbVie’s CEO, Robert Michael, received a significant pay increase to $32.5 million.
(Source：KFF Health News)